Keynote 024 042. Os was significantly improved among patients with tps 50% or more treated with pembrolizumab with 20.0 months compared with 12.2 months among patients who. We present a pooled analysis of safety and efficacy in elderly patients (≥75 years) who received pembrolizumab (a programmed death 1 inhibitor) for advanced non.

Os was significantly improved among patients with tps 50% or more treated with pembrolizumab with 20.0 months compared with 12.2 months among patients who. We present a pooled analysis of safety and efficacy in elderly patients (≥75 years) who received pembrolizumab (a programmed death 1 inhibitor) for advanced non.